Encoded Therapeutics to Present ETX101 Data in Dravet Syndrome at the 2026 ASGCT Presidential Symposium

Encoded Therapeutics Inc., a clinical-stage genetic medicines company, today announced its participation in the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place ...
PharmiWeb

Encoded Therapeutics Doses First Patient in Pivotal Study of ETX101 for Dravet Syndrome and Reports Broader Portfolio Progress

(“Encoded”), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, ...
Business Wire

Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today ...
Nanowerk

Gene Regulation: The Master Control of Cellular Function

Gene regulation is the process by which cells control the expression of their genes, determining when, where, and to what extent each gene is expressed. It is a fundamental mechanism that allows cells ...